Deepak A. Kapoor, MD, Chairman and CEO, Integrated Medical Professionals, PLLC, clinical associate professor, urologic surgery, Icahn School of Medicine at Mount Sinai, chairman, Health Policy at LUGPA, discusses the inclusion of radium-223 in the AUA guideline for castration resistant prostate cancer (CRPC).
In the original release of the 2013 CRPC guideline, radium-223 was not included. This was not an oversight on the part of the AUA, Kapoor says, but rather a timing issue between the drug’s approval and the AUA’s literature review.
To the credit of the process, the AUA recognized that radium-223 is an important drug in the armamentarium of urologists treating patients with CRPC. The AUA did an expedited literature review, and updated the guideline to allow for the use of radium-223 for patients with symptomatic skeletal metastases.
In his practice, Kapoor says he has treated a number of patients with the agent and says that it is an extremely effective form of therapy.
<<< View more from the 2014 AUA Annual Meeting